FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Teva North America ARGATROBAN Injection in 0 Recall

ARGATROBAN Injection in 0

Teva North America · Horsham, PA

Risk level
Class II
Reported by FDA
Sep 14, 2016
Recall ID
D-1494-2016
Check your lot numberHow we source this data

Summary

Teva North America recalled ARGATROBAN Injection in 0 starting Jun 17, 2016. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-1494-2016 on Sep 14, 2016. Reason: CGMP Deviations. Status: Terminated.

Why it was recalled

CGMP Deviations

Product description

ARGATROBAN Injection in 0.9% Sodium Chloride 250 mg/250 mL (1 mg/mL) , Rx Only, Manufactured in Hungary for TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, NDC# 0703-0020-31 (Single Use Bag), NDC # 0703-0020-32 (5 Single Use Bags in One Carton).

Lot numbers, UPCs & expiration codes

All lots within Expiry. Lot # 4720915, 6790315, 6800315, 6810315, 6820315

Where it was sold

Nationwide and Puerto Rico

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-1494-2016
Classification
Class II
Status
Terminated
Recall initiated
Jun 17, 2016
FDA report date
Sep 14, 2016
Quantity
1,299 bags
Recall type
Voluntary: Firm initiated
Recalling firm
Teva North America

Original FDA data

Every field from FDA enforcement report D-1494-2016, exactly as published.

Show all FDA fields
City
Horsham
State
PA
Status
Terminated
Country
United States
Event ID
74497
Address
425 Privet Rd
Code information
All lots within Expiry. Lot # 4720915, 6790315, 6800315, 6810315, 6820315
Postal code
19044-1220
Report date
Sep 14, 2016
Product type
Drugs
Recall number
D-1494-2016
Classification
Class II
Recalling firm
Teva North America
Product quantity
1,299 bags
Termination date
Feb 7, 2017
Reason for recall
CGMP Deviations
Voluntary / mandated
Voluntary: Firm initiated
Product description
ARGATROBAN Injection in 0.9% Sodium Chloride 250 mg/250 mL (1 mg/mL) , Rx Only, Manufactured in Hungary for TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, NDC# 0703-0020-31 (Single Use Bag), NDC # 0703-0020-32 (5 Single Use Bags in One Carton).
Distribution pattern
Nationwide and Puerto Rico
Recall initiation date
Jun 17, 2016
Initial firm notification
Letter
Center classification date
Sep 7, 2016

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-1494-2016, published Sep 14, 2016. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls